Luz Barahona, MD
Pulmonary Disease · Kinston, NCNPI 1821314014
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,400 of the $7,848 with a category attached, or 68.8%. GSK accounts for 74.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $5,523 and has fallen 95.3% since, to $258 in 2025.
Across 43 payments — averaging $182.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$6K
- Olympus Corporation Of The Americas$1K
- AstraZeneca$275
- Boehringer Ingelheim$123
- Mylan Specialty L.p.$118
- Sanofi-aventis U.S. LLC$97
- plus $244 from 6 others
What the payments were for
- Speaking & faculty fees$5,40069%
- Travel & lodging$99713%
- Food & beverage$1,33717%
- Education$1141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 20 | $5,875 |
| Olympus Corporation Of The Americas | 9 | $1,117 |
| AstraZeneca | 3 | $275 |
| Boehringer Ingelheim | 1 | $123 |
| Mylan Specialty L.p. | 1 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Regeneron Healthcare Solutions, Inc. | 1 | $92 |
| Boston Scientific | 2 | $48 |
| Harmony Biosciences LLC | 1 | $36 |
| Masimo Corporation | 1 | $25 |
| Philips North America LLC | 2 | $24 |
| Insmed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$3,125
- TRELEGY ELLIPTA$2,524
- AIRSUPRA$120
- Yupelri$118
How this compares
$7,848 in reported general payments places this provider in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 128 | $608,502 |
| OfevNintedanib Esylate | 39 | $522,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 676 | $486,393 |
| Fasenra PenBenralizumab | 20 | $112,647 |
| XolairOmalizumab | 25 | $104,574 |
| Breo ElliptaFluticasone/Vilanterol | 148 | $71,516 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $60,429 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 84 | $51,355 |
| Dupixent SyringeDupilumab | 11 | $48,570 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 74 | $43,473 |
| Spiriva RespimatTiotropium Bromide | 49 | $38,840 |
| Advair HfaFluticasone Propion/Salmeterol | 99 | $36,315 |
| SymbicortBudesonide/Formoterol Fumarate | 135 | $35,711 |
| Spiriva HandihalerTiotropium Bromide | 54 | $34,650 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $28,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $5,875 | $1,207,9621,040 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $123 | $655,683246 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $275 | $96,140225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Kinston
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.